Technology | 2017.09.08
Replimune Raises $55 Million to Advance its Oncolytic Immunotherapy Programs
WOBURN, Massachusetts, September 8, 2017 /PRNewswire/ -- Replimune Group Inc., a biotechnology company focused on developing next generation oncolytic immunotherapies, announced today the completion of a $55 million Series B financing. The proceeds of the financing will primarily be...
For more information, please visit
http://www.prnewswire.com/news-releases/[...]herapy-programs-643186953.html
